Docking of molecules identified in bioactive medicinal plants extracts into the p50 NF-kappaB transcription factor: correlation with inhibition of NF-kappaB/DNA interactions and inhibitory effects on IL-8 gene expression by Piccagli, Laura et al.
BioMed  Central
Page 1 of 13
(page number not for citation purposes)
BMC Structural Biology
Open Access Research article
Docking of molecules identified in bioactive medicinal plants 
extracts into the p50 NF-kappaB transcription factor: correlation 
with inhibition of NF-kappaB/DNA interactions and inhibitory 
effects on IL-8 gene expression
Laura Piccagli1, Enrica Fabbri1, Monica Borgatti1, Valentino Bezzerri2, 
Irene Mancini3, Elena Nicolis2, Maria C Dechecchi2, Ilaria Lampronti1, 
Giulio Cabrini2 and Roberto Gambari*1
Address: 1BioPharmaNet, ER-GenTech, Department of Biochemistry and Molecular Biology, University of Ferrara, Italy, 2Laboratory of Molecular 
Pathology, Laboratory of Clinical Chemistry and Haematology, University-Hospital, Verona, Italy and 3Department of Biochemistry and 
Molecular Biology, University of Ferrara, Italy
Email: Laura Piccagli - pcclra@unife.it; Enrica Fabbri - fbbnrc@unife.it; Monica Borgatti - brgmnc@unife.it; 
Valentino Bezzerri - valentinobezzerri@hotmail.com; Irene Mancini - mncrni@unife.it; Elena Nicolis - elenni@libero.it; 
Maria C Dechecchi - cristina.dechecchi@azosp.vr.it; Ilaria Lampronti - lmi@unife.it; Giulio Cabrini - giulio.cabrini@azosp.vr.it; 
Roberto Gambari* - gam@unife.it
* Corresponding author    
Abstract
Background: The transcription factor NF-kappaB is a very interesting target molecule for the
design on anti-tumor, anti-inflammatory and pro-apoptotic drugs. However, the application of the
widely-used molecular docking computational method for the virtual screening of chemical libraries
on NF-kappaB is not yet reported in literature. Docking studies on a dataset of 27 molecules from
extracts of two different medicinal plants to NF-kappaB-p50 were performed with the purpose of
developing a docking protocol fit for the target under study.
Results: We enhanced the simple docking procedure by means of a sort of combined target- and
ligand-based drug design approach. Advantages of this combination strategy, based on a similarity
parameter for the identification of weak binding chemical entities, are illustrated in this work with
the discovery of a new lead compound for NF-kappaB. Further biochemical analyses based on
EMSA were performed and biological effects were tested on the compound exhibiting the best
docking score. All experimental analysis were in fairly good agreement with molecular modeling
findings.
Conclusion: The results obtained sustain the concept that the docking performance is predictive
of a biochemical activity. In this respect, this paper represents the first example of successfully
individuation through molecular docking simulations of a promising lead compound for the
inhibition of NF-kappaB-p50 biological activity and modulation of the expression of the NF-kB
regulated IL8 gene.
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Background
The main aim of our molecular modelling investigations
was to identify natural compounds for their ability to
bind to the NF-kappaB p50 as a strategy to identify mole-
cules exhibiting inhibitory activity on the molecular inter-
actions of the transcription factor with its target DNA
sequence. p50–p65 heterodimer is the predominant NF-
kappaB complex in T-cells regulating HIV-1 infection and
recent studies have shown that p50 unit of NF-kappaB is
the one that mainly interacts with HIV-1 LTR [1,2]. The
specific protein residues involved in DNA binding to the
HIV-1 LTR NF-kappaB sites (sequence 5'-GGGACTT-
TCCC-3') have been identified [3,4]. Structurally different
inhibitors of the NF-kappaB/DNA interactions with a
rather low binding constant (in the range of 30 μM and
500  μM) are reported in the literature [5-7]. Recently,
some molecular modelling studies have predicted possi-
ble binding mode of the inhibitors molecules to the DNA
binding region of subunit p50, starting from the crystallo-
graphic structure of the NF-kappaB homodimer [6-9].
In particular, Sharma et al. [8] in an effort to rationalize
the results obtained from EMSA studies on a set of aur-
intricarboxylic acid analogues, employed docking studies
to explain the structure activity relationships observed
within this class. To the best of our knowledge, nowadays
the identification of new lead compounds for NF-kappaB
inhibition through virtual screening of structures libraries
is not yet reported in literature. In this paper, we present
docking studies on a series of natural compounds previ-
ously identified within medicinal plant extracts by us, into
NF-kappaB p50 protein target. After evaluation through
electrophoretic mobility shift assays (EMSA), we obtained
a fairly good agreement between experimental data and




Ligands data and preparation
The database of 27 natural structures used in our molecu-
lar docking studies, were derived from different medicinal
plant extracts (Figure 1) as prepared in our laboratory. A
dataset of 12 active compounds used as references mole-
cules were collected from four publications [6-9] reported
by one laboratory (Figure 2). Ten of these inhibitors (1i-
8i, 11i and 12i) were employed in starting docking studies
(protocol 1) and in the Standard Similarity Scoring for
subsequently docking simulations.
Two inhibitory molecules (9i and 10i) were used as test
set in all docking simulations. The three-dimensional
models of all the molecules under investigation were built
by assembling fragments from the SYBYL 7.0 software
package standard library [10]. Resulting geometries were
optimized and molecular charges were assigned by a semi
empirical molecular orbital calculations using the AM1
Hamiltonian [11] (module MOPAC implemented in
SYBYL).
Proteins data and preparation
The three dimensional structure of the complex NF-kap-
paB-DNA [4] was retrieved from the Protein Data Bank
(PDB code: 1NFK). The cocrystallized DNA macromole-
cule was removed from the structure. p50 dimer and p50
monomers (chains A and B) were selected for the docking
simulations and prepared using the graphical interface
Maestro [12]. All water molecules were removed, the
hydrogen atoms were added to the proteins and all atom
force field (OPSL-2001) charges and atom types were
assigned. Preparation and refinement were done running
ProteinPrep job on the structure in a standard procedure.
Minimizations were performed until the average root
mean square deviation of non-hydrogen atoms reached
0.3 Å.
Docking Simulations
All molecules of plant extracts (1–27) and the known
inhibitors (1i-12i) under study were docked in to the
binding site of the receptor (PDB ID: 1NFK) using Glide
(Grid-Based Ligand Docking With Energetics) software
from Schrodinger [13,14]. Grids were prepared for each
proteins with the exact same center and the size of the
bounding box set on 30 Å. The coordinates of the enclos-
ing box (x = -1,1958 Å; y = 9.0149 Å; z = 19,7598 Å) were
defined starting from the set of active site residues
involved in hydrogen bonds with the NF-kappaB recogni-
tion site of DNA (Arg54, Arg56, Tyr57, Cys59, Lys241,
Gln306 and Thr143) and optimised including the double
strands DNA helices volume by visual inspection. The
Glide algorithm is based on a systematic search of posi-
tions, orientations, and conformations of the ligand in the
receptor binding site using funnel type approach. The
search begins with a rough positioning and scoring phase
that significantly limits the search space and reduces the
number of poses to be selected for minimization on the
precomputed OPLS-2001 van der Waals and electrostatic
grids for the protein. The 5–10 lowest-energy poses
obtained from this stage are subjected to Monte Carlo
simulations and the minimized poses accepted are then
rescored using the GlideScore function, which is a more
sophisticated version of ChemScore [15]. This force field
include additional terms accounting for solvation and
repulsive interactions. In order to provide a better correla-
tion between good poses and good scores, Glide Extra-
Precision (XP) Mode was subsequently used on the con-
formations selected from Glide Standard Precision (SP)
mode. The atom-pair superimposition of p50 chains A
and B, prepared as described above, gave a minimum
RMSD of 2,303 Å (heavy atoms). Considering the clearBMC Structural Biology 2008, 8:38 http://www.biomedcentral.com/1472-6807/8/38
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Structures of compounds found in Cupressus pyramidalis and Aegle marmelos extracts and used for docking simulations Figure 1
Structures of compounds found in Cupressus pyramidalis and Aegle marmelos extracts and used for docking simulations.
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NF-kappaB/DNA binding inhibitors used for atom-pair similarity scoring in docking Figure 2
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dependence of the docking accuracy of ligands on the pro-
tein structure, docking simulations were carried out with
the same protocol on both A and B, considered as two
slightly different conformations of the same structure.
Unfortunately, complexes of NF-kappaB cocrystallized
with inhibitors has not been solved. Therefore, a common
self-docking procedure to evaluate the accuracy of the
docking protocol adopted was not practicable. In order to
overcame this situation, two structurally similar active
compounds (9i and 10i) were used as test set and docked
into the DNA binding site of the protein. Moreover in fol-
lowing docking jobs, atom pair similarity (AP) scoring
(Similscore) facility as implemented in Glide, was incor-
porated in GlideScore (G-score), based on the assumption
that closely related chemical structure should share simi-
lar biological activity and physiochemical property [16].
Similscore can have a value between 0 and 1 as imple-
mented in Glide. The adjusting G-score value is illustrated
here below:
1. if 0.0 ≤ SimilScore < 0.3 → G-score = G-score+6.0
2. if 0.3 ≤ SimilScore < 0.7 → G-score = G-score+(0.7-
Similscore)/(0.7-0.3)*6.0
3. if 0.7 ≤ SimilScore < 1.0 → G-score = G-score+0.0
All inhibitors molecules, except for 9i and 10i, were used
just as reference structures for AP similarity method.
Based on the best final GlideScore ranking, the similarity
docking procedure for subsequently docking simulations
on p50 subunits was chosen.
Preparation of nuclear extracts
Nuclear extracts were prepared as described [18]. Cell
were washed twice with PBS and detached by trypsiniza-
tion. After homogenization with Dounce B homoge-
neizer, nuclear proteins were obtained and protein
concentration was determined using Bio-Rad protein
assay. Nuclear extracts were brought to a concentration of
0.5 μg/μl for Electrophoretic Mobility Shift Assay (EMSA)
experiments [18].
Electrophoretic Mobility Shift Assay (EMSA)
EMSA was perfomed as previously described [18-20].
Briefly, double-stranded synthetic oligodeoxynucleotides
mimicking the NF-κB binding site present in the promoter
of the IL-8 gene (IL-8 NF-κB, sense: 5'-AAT CGT GGA ATT
TCC TCT-3') have been employed. Oligodeoxynucle-
otides were labeled with γ32-P-ATP using 10 Units of T4-
polynucleotide-kinase (MBI Fermentas) in 500 mM Tris-
HCl, pH 7.6, 100 mM MgCl2, 50 mM DTT, 1 mM spermi-
dine, 1 mM EDTA in the presence of 50 μCi γ32-P-ATP) in
a volume of 20 μl for 45 minutes at 37°C. Reaction was
brought to 150 mM NaCl and 150 ng complementary oli-
godeoxynucleotide was added. Reaction temperature was
increased to 100°C for 5 minutes and left diminishing to
room temperature overnight. Nuclear extracts from IB3-1
cells or purified NF-κB p50 dimer protein (Promega) were
used at the specified concentrations and poly(dI:dC) (1
mg per reaction) was also added to abolish nonspecific
binding [21]. After 5 min binding at room temperature,
the samples were run at constant voltage (200 V) under
low ionic strength conditions (0.25× TBE buffer: 22 mM
Tris-borate, 0.4 mM EDTA) on 6% polyacrylamide gels.
Gels were dried and subjected to standard autoradio-
graphic procedures.
Cell cultures and infection with Pseudomonas aeruginosa
IB3-1 cells have been obtained from LGC Promochem
[20]. Cells have been grown in LHC-8 basal medium
(Biofluids), supplemented with 5% FBS in the absence of
gentamycin [21]. All culture flasks and plates have been
coated with a solution containing 35 g/ml bovine colla-
gen (Becton-Dickinson), 1 g/ml bovine serum albumin
(Sigma) and 1 g/ml human fibronectin (Becton-Dickin-
son) as described. P. aeruginosa, PAO1 strain, was grown
in trypticase soy broth (TSB) or agar (TSA) (Difco). Bacte-
ria colonies from o/n cultures on TSA plates were grown
in 20 ml TSB at 37°C. IB3-1 cells were infected with rang-
ing doses of PAO1 at 37°C for 4 hours.
Quantitation of transcripts of inflammatory genes
Total RNA from IB3-1 cells was isolated using High Pure
RNA Isolation Kit (Roche. Mannheim. Germany) [21].
Total RNA (2.5 μg) was reverse-transcribed to cDNA using
the High Capacity cDNA Archive Kit and random primers
(Applied Biosystems) in a 100-μl reaction. The cDNA (2
μl) was then amplified for 50 PCR cycles using the Plati-
num® SYBR® Green qPCR SuperMix-UDG (Invitrogen) in
an ABI Prism 5700 sequence detection system (Applied
Biosystems). The real-time PCR reactions were performed
in duplicates for both target and normalizer genes. Primer
sequences for detection of IL-8 mRNA were GACCACACT-
GCGCCAACA (IL-8 forward) and GCTCTCTTCCATCA-
GAAAGTTACATAATTT(IL-8 reverse). Primer sets were
purchased from Sigma-Genosys (The Woodlands. TX).
Results were collected with Sequence Detection Software
(version 1.3; Applied Biosystems). Relative quantification
of gene expression was performed using the comparative
threshold (CT) method as described by the manufacturer
(Applied Biosystems User Bulletin 2). Changes in mRNA
expression level were calculated following normalization
to calibrator gene [22]. The ratios obtained following nor-
malization are expressed as -fold change over untreated
samples.BMC Structural Biology 2008, 8:38 http://www.biomedcentral.com/1472-6807/8/38
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Results and discussion
Docking analysis
The docking results for all the reference inhibitory com-
pounds and the natural compounds under study are
reported in Table 1 (references compounds) and in Table
2 (natural compounds). As shown in the 2.3 Å crystal
structure, the DNA/p50 complex is formed by one DNA
molecule and two p50 proteins each one consisting of two
distinct domains connected by a10-residue linker. Both
domains and the segments that connects them, form a
sequence-specific DNA-binding surface by contributing 5
loops per subunit that fill the entire major groove of the
DNA. The specific interactions that stabilized the NF-kap-
paB/DNA complex, occur over 10-bp forming the kB rec-
ognition site. Unlike many dimeric protein-DNA
complexes, many residues of both subunits make specific
base contacts in a non-contiguous cooperative network.
The plasticity of centre region of the interface carry to the
lack of symmetry exhibited by the interactions of Lys 241
from the linker segment, and Lys 272 and Arg 305 from
the dimerization region with the symmetrical target site
[4]. In the subsequent experimental EMSA studies, a
recombinant p50 protein that probably forms a mono-
mer-dimer mixture in binding buffer solution will be
used. On the base of structural and experimental assump-
tions as above mentioned, p50 dimer and monomer were
employed as protein target in our molecular modelling
investigation.
In order to evaluate the impact of the introduction of the
similarity penalty in the docking algorithm on the results,
the positions of 9i and 10i used as test set in the final Gli-
deScore ranking were compared in the two different pro-
cedures (Table 2).
Known active compound 10i was ranked at the top posi-
tions in both procedures, but only the introduction of the
similarity parameter in the scoring function significantly
increased the efficiency in 9i ranking (Table 2). In fact the
difference in glide-score among these two inhibitors with
a similar inhibitory potency (500 μM) [9] was very small
(ΔGlideScore = 0.10). For each selected ligand the pose
with best E-Model score (combination of energy grid
score, GlideScore, and the internal strain of the ligand)
was used for in-deph interaction analysis. Compound 21
clearly showed highest score in respect to docked plant
extracts (Table 2) outranking the known inhibitors at
physiological pH in docking simulation to the dimer.
Docked compounds 1–27, 9i and 10i, occupied a region
of the binding surface creates by the spatial relationship
between the N-terminal domain of p50 subunit and the
10 residues long linker loop (Figure 3). Molecules 21, 9i
and  10i  (Figure 4) were located in a small cleft sur-
rounded by several polar amino acids (i.e. Tyr57, His109,
His141, Tyr143 Lys144, Lys145, Ser208, Asp239, Lys241
and Ser208) and the highest score poses were superimpos-
able with minimum RMSD of 1.36 Å for compounds 9i
and 21. The RMSD was calculated by superimposing the
following atoms pairs: heteroatoms involved in hydrogen
bonding with the same residues of the protein (9i.O8 and
21.O2'; 9i.O7 and 21.O1a) (Figure 4B) and the centroid
of aromatic system of coumarin structure with the cen-
troid of benzene ring of 21. These compounds showed
slightly different binding modes in p50 (chain A), p50
(chain B) and p50-p50 targets. Here we reported the high-
est score poses obtained from docking protocol including
the similarity function. H-bond interactions between OH
groups of coumarin structures (OH of benzene ring in 21)
and both NH of His141 and the carboxylic group of
Asp239 showed to be important for ligands binding.
Moreover, OH groups of coumarin moiety (carboxylate
group in 21) made an additional hydrogen bond with CO
of the backbone and protonated NH3 group of Lys241
(Table 3). It is important to note that Lys241 could be
involved in the stability of the DNA-binding conforma-
tion of the protein. In fact, as discussed above, this residue
is situated in the flexible linker segment and interacts with
Lys 272 and Arg 305 from the dimerization domain.
Finally, carbonyl group of 10i engage another H-bond
with NH of the backbone of the Leu207. Compound 21
showed the same binding mode of active ligands in the
monomer configuration of the target, with the only differ-
ence of a stronger interaction of carboxylate group with
Lys241 (Table 3 and Figures 5A, 6A).
Interestingly, the best pose of compound 21 occupied a
region formed by residues of both p50 units (chain A and
chain B) of NF-kappaB dimer: Lys 145 and Thr143 of
chain A and Tyr57, Lys144, Lys145, Glu60, Cys59,
Thr143, Lys146 of chain B. In particular, the OH group of
Table 1: Ranking of the poses of references inhibitory molecules 
(1i-8i and 11i-12i) in the target NF-kappaB p50 both as dimer 
(p50-p50) and as monomers (p50 A and B).
Docking protocol 1
p50-p50 p50 (A) p50 (B)
Cpd. G-Score Cpd. G-Score Cpd G-Score
8i -5.88 8i -6.06 1i -6.08
7i -5.88 7i -5.83 3i -5.35
2i -5.84 11i -5.20 7i -5.06
3i -5.78 1i -5.07 2i -4.58
11i -3.87 2i -2.79 11i -3.59
1i -3.57 3i -2.77 4i -1.82
4i -0.76 4i > 0 8i > 0
12i > 0 12i > 0 12i > 0
5i - 5i > 0 5i -
6i - 6i > 0 6i -BMC Structural Biology 2008, 8:38 http://www.biomedcentral.com/1472-6807/8/38
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the ligand engages a hydrogen bond with the sidechain of
Thr143 (chain B), and the carboxylate group forms a salt
bridge stabilized by two hydrogen bonds with the side
chain of Lys 145 (chain B). Moreover the phenyl structure
of compound 21 could be involved in a weak π-π stacking
interaction with the aromatic moiety of Tyr57 (chain B)
(centroid-centroid distance: 4.93 Å), a residue specific for
kB DNA sequence 5'-GGGATTTCC-3', present in different
cellular genes including HIV-LTR. Of course, further
dynamics simulation on the protein-ligand complex
should be necessary to validate this hypothesis. In addi-
tion, the amino group of Lys145 of the opposite p50 unit
(chain A) could form an additional π-cation interaction
with the aromatic group of 21 (N+-H and centroid of ben-
zene ring distance: 3.87 Å) (Figures 5B, 6B). These bridge
structures are likely to reinforce the anchoring of this mol-
ecule to the DNA binding region of the dimer, and might
account for the slight better G-score of 21 in respect to the
monomer configuration of the receptor. Moreover, all the
residues of the protein involved in molecular interactions
with molecule 21, form hydrogen bonds also with DNA.
All compounds with higher GlideScore and E-Model score
clearly showed the ability to make a maximum number of
hydrogen bonding, according with the result as previously
reported on a flexible docking studies of known inhibitors
9i and 10i [9], even if reported residues involved in bind-
ing interaction were different. The highest ranking poses
Table 2: Ranking of the poses of natural compounds and test set inhibitors (9i and 10i) in the target NF-kappaB p50 both as dimer 
(p50-p50) and as monomers (p50 A and B). In the docking protocol 1 the similarity scoring algorithm is not used.
Docking protocol 1 Docking protocol 2
p50-p50 p50-p50 p50 (A) p50 (B)
Cpd. G-score G-Score Cpd. G-Score Cpd. G-Score
10i -5.61 21 -2.34 9i -3.81 9i -2.13
15 -5.50 9i -2.29 10i -2.27 10i -1.43
25 -5.24 10i -2.19 21 -1.40 21 -0.32
23 -4.94 18 -0.50 18 -0.07 18 > 0
21 -4.91 23 -0.05 10 > 0 15 > 0
24 -4.74 20 > 0 23 > 0 23 > 0
9i -4.44 15 > 0 7 > 0 24 > 0
10 -4.40 25 > 0 8 > 0 10 > 0
20 -4.37 24 > 0 20 > 0 23 > 0
7 -4.28 10 > 0 15 > 0 20 > 0
22 -4.13 16 > 0 25 > 0 16 > 0
16 -3.48 7 > 0 24 > 0 7 > 0
19 -3.71 22 > 0 13 > 0 8 > 0
2 -3.39 19 > 0 12 > 0 2 > 0
27 -3.09 4 > 0 16 > 0 22 > 0
5 -3.05 2 > 0 6 > 0 4 > 0
26 -2.89 5 > 0 9 > 0 1 > 0
18 -2.69 27 > 0 11 > 0 19 > 0
14 -2.47 26 > 0 2 > 0 14 > 0
4 -2.00 14 > 0 3 > 0 5 > 0
Stereoview of compounds 1–27, 9i and 10i docked in to  DNA binding region of the NF-kappaB p50 monomer chain  A Figure 3
Stereoview of compounds 1–27, 9i and 10i docked in to 
DNA binding region of the NF-kappaB p50 monomer chain 
A. The macromolecule is highlighted in green.BMC Structural Biology 2008, 8:38 http://www.biomedcentral.com/1472-6807/8/38
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Superimposition of the docked poses of inhibitors 9i, 10i and compound 21 Figure 4
Superimposition of the docked poses of inhibitors 9i, 10i and compound 21. A. the DNA binding site of NF-kappaB p50 (mon-
omer chain A) is highlighted in green; B. the ligand atoms involved in hydrogen bonding are labeled. Compounds 9i, (shown in 
purple), 10i (shown in blue) and 21 are illustrated in stick representations.BMC Structural Biology 2008, 8:38 http://www.biomedcentral.com/1472-6807/8/38
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of 21, 9i and 10i formed 3–4 hydrogen bonding with the
target protein, whereas molecules in medium positions in
docking ranking not more than 2. According, structures
not involved in hydrogen bonding were ranked in the last
positions (Table 2). In particular, compound 5 with a Gli-
deScore < 0 in similarity protocol lost the ability both to
occupy the same positions of active ligands and to form
hydrogen bonding with the protein (not shown). In
house experimental data were in good agreement with the
molecular modelling findings. In accordance with dock-
ing results, 21 and 5 showed to be active and inactive
respectively in further EMSA experimental studies.
Effects of compound 21 on NF-kappaB/DNA interactions
The effects of compound 21 on NF-kappaB interactions
were first studied by electrophoretic mobility shift assay
(EMSA) as described elsewhere [18-21]. It is indeed well
accepted that molecules binding NF-kappaB might retain
inhibitory activity on molecular interaction between NF-
kappaB and DNA [21]. Accordingly, we performed EMSA
in the presence of increasing amounts of compound 21.
In addition, compounds 5 was used as possible negative
control. This compound, indeed, is expected, from the
docking analysis (Table 2), to be less active. In addition,
extracts from Cupressus pyramidalis were also used, since
this extract does not inhibit NF-kappaB/DNA interactions
(data not shown). Finally, the known inhibitory com-
pound 9i was used as reference molecule. The results of
the gel retardation analysis are shown in Figure 7 and
clearly demonstrate that compound 21 inhibit the molec-
ular interactions between nuclear factors (Figure 7B) or
isolated NF-kappaB p50 (Figure 7C and 7D) and a target
double stranded oligonucleotide mimicking the NF-kap-
paB binding sites. This effect was similar to that exhibited
by the reference compound 9i. Interestingly, compound 5
and extracts from C. pyramidalis were found to be inactive
(Figure 7A), fully in agreement with the docking data
summarized in Table 2.
Biological effects of compound 21: inhibition of 
Pseudomonas aeruginosa mediated increase of IL-8 
mRNA
Several experimental model system are available for bio-
logical validation of molecules inhibiting NF-kappaB
function. In a recent paper we report that decoy oligonu-
cleotides targeting NF-kappaB are powerful inhibitors of
Table 3: intramolecular hydrogen bonds of the docked poses of 
9i, 10i and 21 with the involved residues of the DNA binding 
region of NF-kappaB (see Figure 5 for ligand atom labels). The 
interatomic distances in Angstroms are shown.
Residue interaction Ligand atom Distance (Å)
(His141) -Nε-H::O O5 (9i) 2.12
O8 (10i) 1.88
O2' (21) 1.90
(Asp239) -COO::H H5 (9i) 1.91
H8 (10i) 2.09
H2' (21) 2.00
(Lys241) -CO::H H7 (10i) 1.96
(Lys241) -N+-H::O O7 (9i) 2.60
O1a (21) 2.17
(Leu207) -N-H::O O1 (10i) 2.18
Binding modes of 21 docked in to the active site of NF-kappaB p50: A Figure 5
Binding modes of 21 docked in to the active site of NF-kappaB p50: A. monomer and B. homodimer (chain A, shown in green). 
The residues involved in the interaction with the ligand are shown; the hydrogen bonding and the relative distances are indi-
cated in purple.BMC Structural Biology 2008, 8:38 http://www.biomedcentral.com/1472-6807/8/38
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Pseudomoas aeruginosa mediated induction of IL-8 in cystic
fibrosis IB3-1 cells [21]. Besides the importance of these
data for the theoretical point of view, our results are of
great interest for the practical point of view, suggesting
this treatment as a possible strategy for the therapy of
inflammation associated with cystic fibrosis.
When the effects of P. aeruginosa infection on the expres-
sion of pro-inflammatory genes of IB3-1 cells infected for
4 hours are analysed, the results shown in Figure 8A are
obtained. In this preliminary experiment the content of
RNAs coding for several pro-inflammatory proteins was
analysed by RT-PCR. The results obtained indicate that IL-
8 mRNA sequences sharply increases following PAO1
infection by 40 folds (range 12–92) in respect to basal
level of uninfected cells, assumed to be 1. In addition to
IL-8 mRNA, other genes induced by PAO1 are GRO-γ (15
folds, range 9–36), IL-6 (18 folds, range 5–44), IL-1β (5
folds, range 2–8), ICAM-1 (4 folds, range 2–8). On the
contrary, very low increase of accumulation of IP-10,
RANTES, MIP-1α, TNF-α, IFN-β, TGF-β and IL-10 mRNA
was observed under these experimental conditions.
Since NF-kappaB is one of the most important transcrip-
tion factors regulating the expression of IL-8 gene [23] and
the data reported in Figure 7 demonstrate that compound
21  inhibit NF-kappaB/DNA interactions, we tested the
activity of this compound in inhibiting the expression of
IL-8 gene in IB3-1 cells infected with PAO1. Cells were
exposed to different concentrations of compound 21 and
then infected with 150 cfu/cell of PAO1. After 4 hours,
cells were harvested, RNA extracted and quantitative RT-
PCR analysis performed. The results obtained (Figure 8B)
demonstrate that compound 21 is a strong inhibitor of
PAO-1 induced accumulation of IL-8 mRNA.
Conclusion
In the present work, we carried out docking studies on the
dataset of 27 molecules found in different plant extracts to
NF-kappaB-p50, with the purpose of developing a dock-
ing protocol fit for the target under study, eventually
applicable for more time-consuming virtual screening of
larger database of compounds.
Usually, docking to protein structures that do not have a
ligand present, as in the case of NF-kappaB, dramatically
reduces the expected performance of structure-based
methods. Therefore, the use of NF-kappaB as a target for
virtual docking of natural compounds is not feasible. To
overcome such a limitation, we proposed to enhance the
simple docking procedure by means of a sort of combined
target- and ligand-based drug design approach. Advan-
tages of this combination strategy, based on a similarity
parameter for the identification of weak binding chemical
entities, are illustrated in this work with the discovery of a
new lead compound for NF-kappaB. In this respect, this
paper represents the first example of successfully individ-
uation of a potential lead compound through molecular
docking simulations on a NF-kappaB target. At the same
time, information derived from this structure and its dif-
ferent binding modes, could carry through further lead
optimization to more potent NF-kappaB inhibitors.
In order to validate the approach, biochemical analyses
based on EMSA were performed on compound 21; the
results obtained sustain the concept that the docking per-
formance is predictive of a biochemical activity (Figure 7).
Our results are of interest also from the practical point of
view. The transcription factor NF-kappaB is indeed a very
Poses of docked compound 21 in to the DNA binding region of NF-kappaB p50 Figure 6
Poses of docked compound 21 in to the DNA binding region of NF-kappaB p50. A. monomer and B. homodimer (chain A, 
shown in grey). The inhibitory activity of 21 may be due to its ability to form a stable complex with the active conformation of 
the dimer and/or blocking the interaction of DNA with the monomer filling the protein binding site. The DNA was obtained 
from the crystal structure of the homodimer NF-kappaB (pdb code:1NFK). The surface of the protein is represented in wire 
frame, the ligand and DNA are highlighted in VDW and stick representation respectively.BMC Structural Biology 2008, 8:38 http://www.biomedcentral.com/1472-6807/8/38
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interesting target molecules in the design on anti-tumor,
anti-inflammatory, pro-apoptotic drugs.
In order to validate this last hypothesis, we have
employed human cystic fibrosis IB3-1 tracheal epithelial
cells. We have elsewhere reported that these cells activate,
upon exposure to the bacterium Pseudomonas aeruginosa
(the PAO-1 strain), the expression of several pro-inflam-
matory genes, including those coding interleukin-6 (IL-6)
and interleukin-8 (IL-8). As supported by several groups,
the expression of IL-8 is dependent from NF-kappaB acti-
vation. Accordingly, decoy molecules targeting NF-kap-
paB are strong inhibitors of the IL-8 expression. Therefore,
PAO-1 infected IB3-1 cells are a very interesting model
system to screen for IL-8 inhibitors. The results of our
experiments, in agreement with both docking and EMSA
data, demonstrate that compound 21 is a strong inhibitor
of IL-8 and should be considered of interest for modula-
tion of the expression of this gene.
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